Dustri Online Services

Search Results

Books: 0	Journals: 1	Articles: 1

Original Research

Safety and tolerance of cidofovir as a 2% gel for local application in high-grade cervical intraepithelial neoplasia: A phase 1 investigation

Michel Bossens, Maud Jost, Catherine Van Pachterbeke, Viviane De Maertelaer, Philippe Simon, Francis Frankenne, Philippe Hubert, Brigitte Evrard, Robert Snoeck

Price
42.00 $

Add to Cart

Price

42.00 $

Volume 56 (2018) p. 134 - 141

Abstract

International Journal of Clinical Pharmacology and Therapeutics, Vol. 56 – No. 3/2018 (134-141)

Safety and tolerance of cidofovir as a 2% gel for local application in high-grade cervical intraepithelial neoplasia: A phase 1 investigation

Michel Bossens¹, Maud Jost², Catherine Van Pachterbeke¹, Viviane De Maertelaer¹, Philippe Simon¹, Francis Frankenne², Philippe Hubert³, Brigitte Evrard³, and Robert Snoeck⁴

¹Université Libre de Bruxelles, ULB, Brussels, ²Mithra Pharmaceutical, ³Université ULG, CIRM, and ⁴Rega Instituut, Leuven, Belgium
Objectives: The primary objective was to evaluate the safety and local tolerance of a topical 2% (w/w) cidofovir gel, applied directly to the cervices of women with high-grade cervical intraepithelial neoplasia (CIN 2+). The secondary objective was to evaluate the pharmacokinetics of cidofovir during the treatment. Materials and methods: Nine women with CIN 2+, were treated with a course of 3 g of cidofovir gel, applied locally once per week for 3 weeks in total (9 g). The treatment was administered in a cervical cap, applied to the cervix for 5 or 10 hours (n = 6 and 3 patients, respectively). Follow-up included a structured questionnaire, a gynecological examination, blood analysis for hematology, C-reactive protein (CRP), and renal function assessment plus pharmacokinetic analyses of cidofovir after each treatment and at the end of the full course. Results: No clinically significant hematological/biochemical abnormalities or serious adverse events (SAE) were reported, although 6 mild to moderate adverse events (AE) occurred in relation to the study drug: 1 flu-like syndrome and 5 local AEs. Plasma concentrations of cidofovir were very low (mean C_max of 103.0 and 99.2 ng/mL after 5 and 10 hours of exposure, respectively). Conclusion: Cidofovir, directly applied on CIN 2+, is reasonably well tolerated and the systemic exposure following topical application is much lower than that seen with intravenous administration, at the approved dose. Correspondence to:
Catherine  Van Pachterbeke, PhD 
CHU Brugmann
Place Arthur Van Gehuchten, 4
1020 Bruxelles, Belgium
Email:  [email protected]

Shopping Overview

Shopping Overview
Type	Qtty	Discount	VAT	Price
Your basket is empty

View Cart

Search Results

Shopping Overview

Send us an E-Mail